{"doi":"10.1016/j.numecd.2022.03.001","title":"Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects","abstract":null,"journal":"Nutrition, Metabolism and Cardiovascular Diseases","year":2022,"id":611134,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":790137,"name":"Jeffrey L. Anderson","orcid":"0000-0002-0825-8685","position":1,"is_corresponding":false},{"id":790134,"name":"Heidi T. May","orcid":"0000-0002-7524-5905","position":2,"is_corresponding":false},{"id":1096193,"name":"Viet T. Le","orcid":"0000-0001-6659-5332","position":3,"is_corresponding":false},{"id":1571613,"name":"Oxana Galenko","orcid":null,"position":4,"is_corresponding":false},{"id":232416,"name":"Stavros G. Drakos","orcid":"0000-0002-1223-327X","position":5,"is_corresponding":false},{"id":790136,"name":"Tami L. Bair","orcid":"0000-0002-5744-8370","position":6,"is_corresponding":false},{"id":361776,"name":"Kirk U. Knowlton","orcid":"0000-0003-3544-4130","position":7,"is_corresponding":false},{"id":790138,"name":"Joseph B. Muhlestein","orcid":"0000-0002-3366-9857","position":8,"is_corresponding":false},{"id":855152,"name":"Benjamin D. Horne","orcid":"0000-0002-2656-0263","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects","abstract":"BACKGROUND AND AIMS: Intermittent fasting reduces risk of interrelated cardiometabolic diseases, including type 2 diabetes and heart failure (HF). Previously, we reported that intermittent fasting reduced homeostasis model assessment of insulin resistance (HOMA-IR) and Metabolic Syndrome Score (MSS) in the WONDERFUL Trial. Galectin-3 may act to reduce insulin resistance. This post hoc evaluation assessed whether intermittent fasting increased galectin-3.\nMETHODS AND RESULTS: The WONDERFUL Trial enrolled adults ages 21-70 years with ≥1 metabolic syndrome features or type 2 diabetes who were not taking anti-diabetic medication, were free of statins, and had elevated LDL-C. Subjects were randomized to water-only 24-h intermittent fasting conducted twice-per-week for 4 weeks and once-per-week for 22 weeks or to a parallel control arm with ad libitum energy intake. The study evaluated 26-week change scores of galectin-3 and other biomarkers. Overall, n = 67 subjects (intermittent fasting: n = 36; control: n = 31) completed the trial and had galectin-3 results. At 26-weeks, the galectin-3 change score was increased by intermittent fasting (median: 0.793 ng/mL, IQR: -0.538, 2.245) versus control (median: -0.332 ng/mL, IQR: -0.992, 0.776; p = 0.021). Galectin-3 changes correlated inversely with 26-week change scores of HOMA-IR (r = -0.288, p = 0.018) and MSS (r = -0.238, p = 0.052). Other HF biomarkers were unchanged by fasting.\nCONCLUSION: A 24-h water-only intermittent fasting regimen increased galectin-3. The fasting-triggered galectin-3 elevation was inversely correlated with declines in HOMA-IR and MSS. This may be an evolutionary adaptive survival response that protects human health by modifying disease risks, including by reducing inflammation and insulin resistance.\nTRIAL REGISTRATION: Clinicaltrials.gov, NCT02770313 (registered on May 12, 2016; first subject enrolled: November 30, 2016; final subject's 26-week study visit: February 19, 2020).","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35361560","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0939475322001193?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0939475322001193?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":["Adult","Aged","Biomarkers","Diabetes Mellitus, Type 2","Fasting","Galectin 3","Humans","Insulin","Insulin Resistance","Metabolic Syndrome","Middle Aged","Randomized Controlled Trials as Topic","Water","Young Adult"],"mesh_terms":["Adult","Aged","Biomarkers","Diabetes Mellitus, Type 2","Fasting","Galectin 3","Humans","Insulin","Insulin Resistance","Metabolic Syndrome","Middle Aged","Randomized Controlled Trials as Topic","Water","Young Adult"],"keywords":["Insulin resistance","Metabolic syndrome","Periodic fasting","Therapeutic fasting"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T15:49:36.221725Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}